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Zingiber zerumbet Sm., locally known to the Malay as “Lempoyang,” is a perennial herb found in many tropical countries,
including Malaysia. The rhizomes of Z. zerumbet, particularly, have been regularly used as food ﬂavouring and appetizer in various
Malays’ cuisines while the rhizomes extracts have been used in Malay traditional medicine to treat various types of ailments (e.g.,
inﬂammatory- and pain-mediated diseases, worm infestation and diarrhea). Research carried out using diﬀerent in vitro and in
vivo assays of biological evaluation support most of these claims. The active pharmacological component of Z. zerumbet rhizomes
mostwidelystudiediszerumbone.Thispaperpresentsthebotany,traditionaluses,chemistry,andpharmacologyofthismedicinal
plant.
1.Introduction
Considered as a moderately large genus of herbs belonging
to the family Zingiberaceae, genus Zingiber is represented
by approximately 141 species that are distributed mainly
in Asia. This genus of plant is conﬁned to the tropics of
Asia, Malaysia, and the Paciﬁc Islands [1, 2]. The name
Zingiber, actually derived from a Sanskrit word that refers
to bull’s horn [3]. One particular plant of this genus that
has gained much interest from scientists all over the world
because of its high medicinal values is Zingiber zerumbet
(L.) Smith.Z .z e r u m b e t , commonly known as the pinecone
or shampoo ginger, is a perennial, tuberous root herb plant
that can be found growing naturally in damp, shaded parts
of the lowland or hill slopes, as scattered plants or thickets.
It is known by various names, for example, “Lempoyang”
(Malaysia and Indonesia), “Ghatian”a n d“ Yaiimu” (India),
“Jangli adha” (Bangladesh), “Awapuhi” (Hawaii), “Zurun-
bah”( A r a b ) ,“ Hong qiu jiang” (China), and “Haeo dam”o r
“Hiao dam” (Northern Thailand) [4–8]. This herbal plant is
believed to be native to India and the Malaysian Peninsula,
and since it has been cultivated for so long in so many
places throughout Southeast Asia, the Paciﬁc, and Oceania,
it became uncertain as to where the plant had originated. Z.
zerumbet has also been claimed to be introduced throughout
the Paciﬁc by the ancient Polynesian settlers [9].
Z. zerumbet can be characterized by the presence of
a pulvinus between the base of the petiole and ligule
[10] and is a variegated wild edible ginger with stems of
approximately 1-2m tall that are erect, oblique, round,
annual and invested by the smooth sheaths of the leaves.
The leaves and inﬂorescences of the pinecone ginger crop
up from a thick knobbly rhizome or the underground stem
that grows just under the surface of the soil (Figure 1).
The leaves, which are sometimes purplish beneath young
shoots, are thin approximately 25–35cm long with their
midribs strongly raised on the lower surface. The petiole is
approximately 6mm long while the ligule, which is very thin,
entire, and broad, is approximately 1.5–2.5cm long. The
leaﬂets are arranged alternately along an arching pseudostem
that grows 1-2m in length. The inﬂorescence, which is
approximatly 6–12cm long and green when young and2 Evidence-Based Complementary and Alternative Medicine
Figure 1: The leaves and inﬂorescences of Z. zerumbet.
becomes red when old, is borne on a separate pseudostem
from the leaves and has closely overlapping bracts or bracts
that form an open pouch in which ﬂowers occur, one in each
bract (Figure 2). It is a spike, ovoid to ellipsoid in shape;
bracts subtend the position of each of the ﬂowers giving the
inﬂorescence its pinecone shape. Z. zerumbet is also known
as shampoo ginger because the mucilaginous substance
present in the inﬂorescence is used by the Hawaiians as
shampoo and natural hair conditioner [10, 11]. The bracts
are approximately 3–3.5cm long and 2.5cm wide while the
bracteole is approximately 2.5cm long, wide and thin but
persistent until fruiting. The pale yellow or white ﬂowers,
which are usually longer than bracts, fragile, ephemeral and
only lasting a few hours, produce in August and September
[11] and emerge from the lowest bracts ﬁrst, and when
exhausted, the ﬂower dries and falls away. The lip of the
ﬂower is three lobed. After ﬂowering, the bracts change
colour,whichcontinuesupwarduntiltheentireinﬂorescence
is bright crimson. The corolla tube is as long as the bract
while the style is long and ﬁliform. The stigma is slightly
projecting and its margin is ciliate. The unique characteristic
of Z. zerumbet and other plant within this genus is that
the stamen, which dehisces longitudinally, is attached with
a long curved beak or horn-like appendage. One stamen
of the inner whorl is fertile, and the two staminoids have
petal-like shape. The ovary is inferior and trilocular with
axile placentation. Fruit is white, glabrous, thin walled and
approximately 1.5cm long. The seeds, which are covered
with lacerate aril, are ellipsoid and black [10, 12]. The
most important part of Z. zerumbet is its rhizomes, which
have been associated with all the claimed medicinal uses.
The rhizome of Z. zerumbet, which is perennial, thick,
scaly, aromatic, and pale yellow internally (Figure 3), is used
exclusively by this obligates asexual reproducer plant for
propagation.
The rhizome of Z. zerumbet (RZZ), in particular, has
been used traditionally as herbal medicine in Asian, Indian,
Figure 2: The inﬂorescences of Z. zerumbet.
Figure 3: The rhizomes of Z. zerumbet.
Chinese, and Arabic folklores since ancient times. Despite its
regular uses as food ﬂavoring and appetizer in Malays and
Indian cuisines, the rhizomes of Z. zerumbet,i np a r t i c u l a r ,
have also been used in folkloric medicine as a cure for
various ailments [13–15]. Many reviews have appeared
in the literature regarding Z. zerumbet particularly on
its medicinal uses but none have described the complete
chemical and pharmacological properties of this important
ethnomedicinal plant. Therefore, we aimed to compile an
up-to-date and comprehensive review of Z. zerumbet that
covers its ethnomedicinal uses, phytochemical contents, and
pharmacological activities.
2. Ethnomedicinal/TraditionalUses
Various ginger spices of the Zingiberaceae family are widely
used as spices, ﬂavouring agents, and medicines in Southeast
Asia because of their unique ﬂavour as well as due to theirEvidence-Based Complementary and Alternative Medicine 3
medicinal properties. Some of the RZZ traditional usages as
botanical medicine include the treatment of inﬂammation,
fever, toothache, indigestion, constipation, diarrhea, severe
sprains, and to relieve pain, as well as antispasmodic,
antirheumatic, and diuretic agents [5–7, 14, 16]. Other than
that, the Malays used the fresh rhizomes as a cure for edema,
stomachache,sores,andlossofappetitewhilethejuiceofthe
boiled rhizomes is used to treat worm infestation in children
[1, 14, 17, 18]. In Thailand, the fresh rhizomes are also used
as antiﬂatulent agent. Meanwhile, the Chinese macerated the
rhizomes in alcohol and use it as a tonic, depurative, or
stimulant while the Taiwanese used the plant as an anti-
inﬂammatory adjuvant for stomach ache, sprain, and fever.
In India, the rhizome powder is mixed with ripe Morinda
citrifolia for the treatment of severe pain, the cooked and
softened rhizome is used to treat toothache, cough, asthma,
worms, leprosy, and other skin diseases, and the ground
and strained rhizome is mixed with water and drank to
treat stomach ache [7]. The Hawaiians apply the compressed
RZZ to sore spots, bruises, and cuts and also used it to
treat headaches, toothache, ringworm/other skin disease,
achyjoints/sprains,stomach-ache.Inaddition,theyalsoused
ashes from burnt Z. zerumbet leaves, which are combined
with a mixture of ashes of Schizostachyum glaucifolium,n u t
sap of Aleurites moluccana,a n dt u b e rs a po fZ. zerumbet,
as a remedy for cuts and bruised skin while the RZZ was
mashed with salt and rubbed on the head to treat headaches
[19, 20]. Furthermore, the plant’s pine cones are used as
an ornamental in gardening, and the milky juice obtained
from the pine cones is famously used as a shampoo in
Hawaii [21].
3. Phytochemical Contents
Of all parts of the plant, the RZZ has been the subject
of extensive chemical investigations because of its high
medicinal values. Various reports have been published
regarding the phytochemical content of RZZ. Attempts to
isolate and identify bioactive compounds from the RZZ had
started since 1944 with the identiﬁcation of humulene [22],
monoterpenes [23, 24], and zerumbone (2,6,10-cy-cloun-
decatrien-1-one, 2,6,9,9-tetramethyl-,(E,E,E)-) [24]f r o m
the essential oil of RZZ (EOZZ). This is followed by the
success of Ramaswami and Bhattacharyya [25] in identifying
two new oxygenated derivatives of humulene (humulene
monoxide and humulene dioxide) and Nigam and Levi
[26] in reporting the presence of 8 fractions when the
EOZZ was subjected to the column chromatography with
petroleum ether, benzene, ether, and methanol used as
eluants. Those fractions were reported to contain α-pinene,
β-pinene, Δ3-carene, camphor, β-caryophyllene, ar-curcu-
mene, zerumbone, humulene oxide, humulene dioxide,
linalool, borneol, α-terpineol, unidentiﬁed sesquiterpene
ketones and sesquiterpene alcohol. Meanwhile Damodaran
and Dev [27, 28] reported the isolation of new sesquiterpe-
noids (e.g., humulene epoxide-I, humulene epoxide-II,
humulenol-II, dihydro-ψ-photo-zerumbone and ψ-photo-
zerumbone) and sesquiterpene alcohols (humulenol-I and
humulenol-III) from the sesquiterpene fractions and EOZZ,
respectively. Chhabra et al. [29] have successfully isolated
zerumbone oxide from RZZ while Matthes et al. [30]
managed to isolate one new (3  ,4   -0-diacetylaﬁelin) and
ﬁve known compounds (zerumbone, zerumbone epoxide,
diferuloylmethane, feruloyl-p-coumaroyl-methane and di-
p-coumaroyl-methane) from pentane and ether extracts of
RZZ, respectively. Masuda et al. [31] have successfully iso-
lated three new acetylated (3-O-(2-O-acetyl-α-L-rhamno-
pyranoside),3-O-(3-O-acetyl-α-L-rhamnopyranoside),3-O-
(4-O-acetyl-α-L-rhamnopyrano-side)) and one known (3-
O-α-L-rhamnopyranoside) kaempferol glycosides from
the acetone extract of the fresh RZZ. Dung et al. [32, 33]
reported high proportions of (Z)-nerolidol (22–36%) in
extracts of stems, leaves, and ﬂowers, but not rhizomes,
and found zerumbone to predominate in leaves. Further
phytochemical investigations demonstrated the presence
of sesquiterpenoids, ﬂavonoids, aromatic compounds (e.g.,
hydroxybenzaldehyde), vanillin and kaempferol derivatives
in the RZZ [34–36]. The ethyl acetate fractions of the RZZ
(EAZZ) have been reported to contain kaempferol-3-O-
rhamnoside, kaempferol-3-O-(2  -o r3   -acetyl) rhamno-
side, kaempferol-3-O-(4  -acetyl) rhamnoside, kaempferol-
3-O-(3  ,4   -diacetyl)rhamnosideandkaempferol-3-O-(2  ,
4  -diacetyl) rhamnoside [18], which concur with report
by Lako et al. [37] on the presence of high content of
kaempferol in the RZZ. All reports mentioned above were
further conﬁrmed by ﬁndings of Srivastava et al. [38]a n d
Yu et al. [39] who reported the presence of approximately
86% sesquiterpenoids with zerumbone being the major
component in the EOZZ. Yu et al. [39] also reported the
presence of β-caryophyllene, caryophyllene oxide and
β-eudesmol in the EOZZ. Besides having zerumbone as its
main constituent, earlier study also reported that the EOZZ
has characteristics of being dextrorotatory and congeals
at 3◦C[ 40]. In contrast to these ﬁndings, the EOZZ of
another proposed variety of Z. zerumbet was characterized
as being levorotatory, congeals at −27◦C and contains
4-terpinenol as its main constituent. In a latest study,
attempt to identify anti-inﬂammatory compounds from the
rhizome of Z. zerumbet led to isolation of one sesquiterpene
(zerumbone), one ﬂavone (3-O-methyl kaempferol), and
two ﬂavonoid glycosides (kaempferol-3-O-(2,4-di-O-acetyl-
α-L-rhamnopyranoside) and kaempferol-3-O-(3,4-di-O-
acetyl-α-L-rhamnopyranoside)) from the methanol extract
of Z. zerumbet (MEZZ) [36]. According to Dae et al. [34]
study on the chloroform soluble fraction of Z. zerumbet
led to the isolation and identiﬁcation of two aromatic
compounds, p-hydroxybenzaldehyde and vanillin, and six
kaempferol derivatives. Chane-Ming et al. [41] reported the
EOZZ was rich in zerumbone, α-pinene, and camphene.
In contrast, the oils from leaves and ﬂowers contained high
amount of (E)-nerolidol, β-caryophyllene, and linalool,
respectively, with the former diﬀered from the others by
their high levels of α-a n dβ-pinene. In addition to these,
leaves and ﬂowers also contain zingiberene [5]. Interestingly,
in most of the studies that described the presence of
zerumbone, the compound has been reported as the
predominant compound in RZZ. Recent study revealed the
presence of a sesquiterpene, zederone, in ethanol extract of4 Evidence-Based Complementary and Alternative Medicine
RZZ (EEZZ) [42]. Phytochemical screening to the aqueous
extract of RZZ (AEZZ) was reported to contain phenolic,
saponins, and terpenoids [43].
4.PharmacologicalProperties
Various studies have revealed the diﬀerent pharmacological
potentials of Z. zerumbet in a range of in vitro and
in vivo test models. The RZZ, in particular, has been
demonstrated to possess anti-inﬂammatory, antinociceptive,
antiulcer, antioxidant, anticancer, antimicrobial, antihyper-
glycemic, antiallergic, antioxidant, and antiplatelet activities
at diﬀerent doses/concentrations. These have been described
in greater detail in the following subsections.
4.1. Acute Toxicity. The AEZZ at 2000mg/kg body weight
did not cause any behavioral changes to the broiler chickens
immediately after its administration indicated by normal
movement and drinking behavior [43]. However, after 1
hour the extract-treated birds exhibited signs of inappetence
which lasted until 24 hours after the extract administration.
Interestingly, no mortality was recorded until 14 days of the
extract administration while histopathological observation
of the livers and kidneys at macroscopic and microscopic
levels indicated no alteration to the treated organs. The
clinical blood chemistry examination indicated signiﬁcant
increases in the serum level of ALT, ALP and AST of female
broiler after 7 and 14 days of treatment with the 2000mg/kg
bodyweightAEZZwhencomparedtothecontrolgroup.The
serum values of ALT, ALP and AST at 0, 7 and 14 days after
the extract administration were 2.94 ± 0.12, 11.10 ± 1.06,
and 6.84 ± 0.15; 2168 ± 170, 2580 ± 172, and 3117 ± 155;
202 ± 14.83, 279 ± 13.04, and 198 ± 2.36 as compared to
the control group (2.68 ± 0.14, 5.34 ± 1.14, and 5.66 ± 0.15;
2224 ± 143, 3339 ± 323, and 2531 ± 196; 202 ± 11.56, 263
± 13.11, and 215 ± 14.62, resp.). Furthermore, the serum
total protein, albumin, globulin, creatinine, and urea level
of extract-treated broiler was not signiﬁcantly diﬀerent when
compared to the control group when measured immediately
and 7 days after the extract or vehicle administration.
However, 14 days after the test solutions administration,
only the serum level of urea increased signiﬁcantly in the
broilers treated with AEZZ extract. The eﬀects of 2000mg/kg
AEZZ on broilers’ feed intake, body weight gain and feed
conversion ratio were also measured whereby the extract
signiﬁcantly increased the body weight of broilers at 7 and 14
days after its administration. The extract was also found to
signiﬁcantly increase food consumption until the end of the
experiment (35 days) when compared to the control group.
4.2. Antinociceptive Activity. Somchit et al. [44]h a v ee a r l i e r
reported on the antinociceptive proﬁles of AEZZ and EEZZ
administered intraperitoneally into rats and assessed using
the0.6%aceticacid-inducedwrithingtest.Inthisstudy,only
the EEZZ was found to be signiﬁcantly (P<. 05) eﬀective
in reducing the number of writhing in a dose-dependent
manner. The activity was observed at the lowest dose
(10mg/kg) 20min after the phlogistic agent administration
in rats and lasted until the end of experiment (40min).
Morphine, at the doses of 2 and 8mg/kg, was used as the
standard reference drugs. Interestingly, the 25 and 100mg/kg
EEZZ antinociceptive activity was comparable to that of 2
and 8mg/kg morphine, respectively.
Recent studies using the MEZZ (25, 50, and 100mg/kg;
given subcutaneously) and EOZZ (30, 100, and 300mg/kg;
given intraperitoneally) demonstrated that the extract and
oil exhibited signiﬁcant (P<. 05) antinociceptive activity
at the peripheral and central levels when assessed using
the writhing, hot plate, and formalin tests [6, 14]. Inter-
estingly, the antinociceptive activity of MEZZ and EOZZ
was attenuated by 5 mg/kg naloxone indicating that the
antinociceptive activity observed was modulated partly via
the opioid receptor system. The ability of both MEZZ and
EOZZ to inhibit nociception in the hot plate test and in
both neurogenic and inﬂammatory phases of the formalin
test suggested that the antinociceptive activity involved
peripheral and central mechanism of actions. Compari-
son of extract’s antinociceptive activity was made against
100mg/kg ASA and 5 mg/kg morphine, which represent
the peripherally and centrallyacting antinociceptive agent,
respectively. ASA produced approximately 63% antinocicep-
tion in the writhing test when compared against the MEZZ
thatgaverangebetween17–55%antinociception.Morphine,
on the other hand, exerted high antinociceptive activity as
indicated by increase of latency against discomfort 90min
after its administration while 100mg/kg MEZZ exerted high
antinociceptive activity 120min after its administration.
Furthermore, ASA and morphine produced 8% and 63%
antntinociception in the ﬁrst phase and 67% and 23%
antinociception in the second phase of the formalin test. In
comparison, MEZZ produced approximately 27–45% and
34–62% antinociception in both phases, respectively.
4.3.Anti-InﬂammatoryActivity. Theanti-inﬂammatorypro-
ﬁle of intraperitoneally administered AEZZ and EEZZ, at the
doses of 25–100mg/kg, against prostaglandin-E2-(PGE2-)
inducedpawedematesthasbeenreportedearlierbySomchit
and Nur Shukriyah [17]. The AEZZ exhibited signiﬁcant
anti-inﬂammatory activity only at the doses of 50 and
100mg/kg with the former dose producing an activity
between 1–4h while the latter exhibiting an activity between
0.5–4h after PGE2 administration. On the other hand, the
EEZZ failed to aﬀect the PGE2-induded paw edema at all
doses tested. Mefenamic acid, at the dose of 20mg/kg,
w a su s e da ss t a n d a r dd r u ga n dp r o d u c e dp e a ke ﬀects of
approximately 50% inﬂammatory inhibition for the ﬁrst 2h
after its administration before being constantly reduced until
it reached 30% inhibition at the end of the experiment
(at interval time of 4h). The AEZZ with percentage of
inﬂammatory inhibition of approximately 50% was found to
produce anti-inﬂammatory activity that was comparable to
that of mefenamic acid for the ﬁrst 2-hour-interval.
The MEZZ (25–100mg/kg; given subcutaneously) also
demonstrated signiﬁcant (P<. 05) antiedema and anti-
inﬂammatory activities when assessed using the acute
(carrageenan-induced paw edema test) and chronic (cotton-
pellet-induced granuloma test) models of inﬂammation,
respectively [6]. All dosages of MEZZ exhibited signiﬁcantEvidence-Based Complementary and Alternative Medicine 5
antiedema activity in the paw edema test in a concentration-
dependent manner. The onset of antiedema eﬀect of 50
and 100mg/kg MEZZ was 1.5h after the phlogistic agent
administraton while for 25mg/kg extract, the onset of
antiedema was 2.5h after the carrageenan administration.
Overall, the antiedema activity of MEZZ, which lasted until
the end of experiment (6.5h), was lower than 100mg/kg
ASA. In addition, all doses of MEZZ also signiﬁcantly
reduced the weight of exudates and granuloma tissues in the
granuloma test in a dose-dependent manner. The 50mg/kg
MEZZ caused 47% reduction in the weight of exudates and
52% reduction in granuloma tissues. Additional study using
theisolatedrat’sileumpreparationdemonstratedthatMEZZ
also aﬀected the organ contraction induced by bradykinin,
PGE2 and histamine [6]. Further study using the EOZZ
also revealed the oil potential as anti-inﬂammatory agent
based on its ability to attenuate inﬂammation induced in
both tests mentioned earlier when given intraperitoneally
[7]. Interestingly, the EOZZ was also reported to attenuate
the second phase of the formalin-induced pain test, which
is associated with inﬂammatory-mediated pain [7]. In both
reports [6, 7] 100mg/kg ASA was used as a standard
reference drug in carrageenan-induced paw edema and
cotton-pellet-induced granuloma tests. The ASA exerted
signiﬁcant anti-inﬂammatory activity that was comparable
to 100mg/kg MEZZ in the paw edema tests and to 50
and 100mg/kg MEZZ in the granuloma test. The ASA
also exerted greater anti-inﬂammatory activity against the
30, 100, and 300mg/kg EOZZ in the ﬁrst 3h after its
administration in the paw edema test, but this activity
reduced signiﬁcantly for the next 2h at which the 100
and 300mg/kg EOZZ activity increased remarkably. In the
granuloma test, the 100mg/kg ASA produced approximately
60%antitransudativeandantiproliferativeactivities.Incom-
parison, the 30–300mg/kg EOZZ produced both activities in
the range of 60–75% and 42–66%, respectively.
4.4. Antipyretic Activity. The intraperitoneally administered
AEZZ and EEZZ, at the doses of 25, 50, and 100mg/kg,
were reported to exert antipyretic activity when assessed
for 8h using the Brewer’s yeast-induced pyrexia test [44].
Both extracts demonstrated dose-dependent antipyretic
eﬀect with the EEZZ signiﬁcantly reducing the rat’s rectal
temperature only at the doses of 50 and 100mg/kg while
the AEZZ was eﬀective at all doses used. Unfortunately,
the antipyretic potential of both extracts was not compared
against any standard reference drugs.
4.5. Hepatoprotective Activity. Further study on hepatotoxic-
ity potential of RZZ demonstrated that the crude AEZZ, at
the doses of 50 and 500mg/kg, did not cause hepatotoxicity
eﬀect in mice, which concurred with the insigniﬁcant
changes in the serum level of ALT and AST after treatment
for 4 weeks [45]. Although the AEZZ did cause elevation
in serum creatinine level, there are no pathological renal
disorders seen. This is further supported by the insigniﬁcant
changes in the serum blood-urea-nitrogen (BUN) levels
between the parallel control (PC) and treated mice indi-
cating normal renal function. In anti-inﬂammatory study,
the AEZZ signiﬁcantly inhibited the release of TNF-α in
murine peritoneal macrophages following LPS stimulation,
which occurred in a dose-dependent manner, and TNF-α
expression by 55% and 38%, respectively. The AEZZ was
also found to inhibit inteleukin-4 (IL4)p r o d u c t i o ni nE L - 4
lymphocytes at the dose of 500μg/mL. Compounds like 6-
gingerol, kaempferol glycosides and kaempferol derivatives,
and chromenone, but not zerumbone, were suggested to
contribute to the observed anti-inﬂammatory activity of the
crude AEZZ. The authors suggested that zerumbone was
not one of them as it did not dissolve easily in water-
soluble fractions. In antipulmonary inﬂammatory study,
the AEZZ was also found to signiﬁcantly reduce cysteinyl
leukotriene(LTC4)(39%reduction)releasebythelungtissue
of treated mice when compared to the control mice (429
± 69 versus 261 ± 23ρg/lung) without aﬀecting the serum
level as interleukin-1α (IL1α) suggesting that the extract is
not inducing any inﬂammatory eﬀect upon long-term oral
administration to mice and is not causing any harmful eﬀect
t ot h el i v e ro rt or e n a lf u n c t i o n .L T C 4 plays a signiﬁcant role
in the pathophysiology of asthma. These ﬁndings suggested
the potential of AEZZ in improving symptoms of asthma
without exacerbating inﬂammatory reactions. In in vivo
anti-hypersensitivity study, the AEZZ as well as PC group
caused signiﬁcant increase in mRNA expressions of both IL4
and IFNγ in the splenocytes of mice induced with allergic
inﬂammation when compared to control group. Moreover,
the AEZZ as well as the PC group also increased gene
expressions of IL4 and IFNγ levels that were 3, 50, 11, and
12 times, respectively, when compared to the normal group
in the ConA-stimulated splenocytes. In mice not stimulated
with ConA, the gene expressions of IL4 and IFNγ levels
increased about 30-, 4-, 12-, and 20-fold in extract-treated
mice and PC group compared to the NC group, respectively.
Overall, the AEZZ was found to signiﬁcantly increase
gene expression of interferon-γ (IFNγ) while signiﬁcantly
reducing the expression of IL4 gene expression in splenocytes
stimulated with ConA or without ConA, whereby both
mediators are involved in the regulation of immune response
during human asthmatic attacks. In addition, the AEZZ also
increased the ratios of splenocyte IFNγ/IL4 gene expression
by 5- and 12-fold when compared to the ratios of NC group,
which suggested that the allergic asthmatic reactions might
beeliminatedvialong-termupregulationoftheT-helper1/T-
helper2 (Th1/Th2) response during the modulation of the
cytokine gene expression in immune cells. These ﬁndings
revealed the potential of RZZ to exert anti-inﬂammatory
and anti-hypersensitive activities via its ability to inhibit the
synthesis of LTC4 and through the immunomodulation of
Th1/Th2 cytokine production.
4.6. Antiallergic Activity. The EEZZ and AEZZ and volatile
oilofRZZ(VOZZ)weresubjectedtoaninvitroinvestigation
for their antiallergic activity [46] .T h ee x t r a c t sa n do i l ,a t
the concentrations of 0–100μg/mL, were investigated for its
ability to inhibit the release of β-hexosaminidase from RBL-
2H3 cell line. The EEZZ and AEZZ inhibited the release
of β-hexosaminidase from the cells between 10–100μg/mL
with inhibitory percentage of 8.4–53.7% and 10.9–59.1%,6 Evidence-Based Complementary and Alternative Medicine
respectively. The IC50 value obtained for both extracts was
91.0 and 68.2μg/mL, respectively. In comparison, the stan-
dard drug, ketotifen fumarate, at doses ranging between 0–
100μg/mL, exhibited inhibitory percentage ranging between
0–68.2% with IC50 value of 20.2μg/mL (47.5μM). On the
other hand, the VOZZ failed to inhibit β-hexosaminidase
at all concentrations tested. The EEZZ, AEZZ, and VOZZ
were also found to be inactive against the enzyme activity
of β-hexosaminidase. Overall, comparison with other plants
of the Zingiberaceae family suggested that RZZ possessed
moderate antiallergic activity.
4.7. Immunomodulatory Activity. Thirty six crude chloro-
form, methanol and water extracts of 11 medicinal plants
commonly used in Thailand were screened for activating
human lymphocytes and phagocytes activities [47]. The
marker used for detecting lymphocyte activation and pro-
liferation via ﬂow cytometer were CD69 antigen expression
while eﬀects on phagocytes were detected by measuring the
migration of polymorphonuclear cells towards a chemoat-
tractant under agarose. The chloroform extract of RZZ
(CEZZ) signiﬁcantly stimulated T lymphocytes to express
CD69 antigen by 31.6% as compared to the control group
(6.2%). The MEZZ and AEZZ gave percentage stimulation
of CD69 antigen of 5.8% and 2.3%, respectively. None of
the crude extracts stimulated the migration of polymor-
phonuclear cells but CEZZ and MEZZ did suppress poly-
morphonuclearcellsmigration.Phytohemagglutinin(PHA),
at the concentration of 5μg/mL, was used as positive control
drug to stimulate the CD69 expression on lymphocytes with
an incubation period of 4h and gave an approximately 46%
stimulation of lymphocytes. However, no positive control
was used to compare the polymorphonuclear migration rate
potential of those extracts.
4.8. Antiplatelet Aggregation Activity. The MEZZ, together
with another 48 methanol extracts of 37 species of Malaysian
medicinal plants, were investigated for their ability to
inhibit platelet-activating factor (PAF) receptor-binding
eﬀects using rabbit platelets [48]. At the concentrations
of 18μg/mL, the MEZZ produced approximately 96.4%
inhibitory eﬀect, which is the highest as compared to the
other plants’ extracts, with Boesenbergia pandurata’s extract
being the only plant with closest inhibitory eﬀect (80.4%).
Interestingly, the inhibitory eﬀect of MEZZ was greater
than Cedrol, a known PAF antagonist (85.2%), which was
used as the standard drug. The IC50 value obtained for the
active MEZZ was 1.2 ± 2.0μg/mL, which was the lowest
compared to Cedrol (2.4 ± 1.3μg/mL) and B. pandurate (8.6
± 2.6μg/mL).
The MEZZ was also reported to exhibit strong anti-
platelet aggregation activity at 100μg/mL in human whole
blood in vitro, with all extracts exhibiting 100% inhibition
[49]. ASA, used as a positive control at the concentration
of 25μg/mL, exhibited inhibitory eﬀects of 100%, 31% and
43% against arachidonic acid-, collagen- and ADP-induced
platelet aggregation. Interestingly, compound isolated form
RZZ, zerumbone, at the concentration of 100μg/mL, exerted
strong inhibition on platelet aggregation induced by arachi-
donic acid, collagen and ADP with inhibitory eﬀects of
100%, 68%, and 100%, respectively.
4.9. Antioxidant Activity. Fruits and vegetables are known
to contain various forms of phytochemicals and antioxi-
dants, particularly polyphenol compounds (e.g., ﬂavonoids
and anthocyanins). Their frequent consumption has been
associated with a lowered risk of heart disease, cancer,
hypertension, and stroke. RZZ, which is a widely used herb
taken before meals especially in Fiji, is reported to be the
richest source of kaempferol (240 mg/100 g) when compared
to another species of Zingiberaceae (Z. oﬃcinale)[ 37]. Z.
oﬃcinale contained only trace amount of kaempferol. Other
than kaempferol, RZZ contained <1mg/100g of myricetin,
ﬁsetin and quercetin. Comparison of Z. oﬃcinale,w h i c h
possessed total antioxidant capacity (TAC) of 320mg/100g
and total polyphenol content (TPC) of 200mg/100g, also
revealed that RZZ contained TAC of 18mg/100g and TPC
of 130mg/100g. For comparison purpose, Trolox C (0.06–
0.5mg/mL), gallic acid (0.1–0.5mg/mL) and ﬂavonol (5–
20μg/mL), and carotenoids (lycopene and β-carotene) (5–
20μg/mL) were used.
4.10. Cytotoxic Activity. In an attempt to ﬁnd plant(s) with
potential antitumour promoting agent(s), several medicinal
Zingiberaceae rhizomes commonly found in Malaysia were
screened using the short-term assay of inhibition of 12-O-
tetradecanoyl phorbol-13-acetate- (TPA-) induced Epstein-
Barr virus early antigen (EBV-EA) in Raji cells [8]. The
assay used to detect the inhibition of TPA-induced EBV-EA
was the indirect immunoﬂuorescence assay (IFA) followed
by the Western blot technique. For comparison purposed,
1000μM ascorbic acid, a known antitumour promoter, was
used as a standard and exhibited 50% inhibitory eﬀect
against TPA-induced EBV-EA activation in Raji cells when
comparedwithnegativecontrol.Sevenplants’rhizomes(20–
640μg/mL), including RZZ, possessed inhibitory activity
towards EBV activation, induced by TPA. The others are of
Curcuma domestica, C. xanthorrhiza, Kaempferia galanga, Z.
cassumunar, Z. oﬃcinale and Z. oﬃcinale (red variety). The
CEZZ and EEZZ were reported to express EBV (Epstein-
Barr virus) activation inhibitory activity when tested at
the dose range of 20–160 and 70–320μg/mL cell culture
medium, respectively [8]. Both extracts were also found
to cause suppression of 12-O-tetradecanoyl phorbol-13-
acetate-(TPA-) induced EBV-EA-D (EBV-early antigen) and
EA-R (restricted EA complex) protein production in Raji
cells when detected using the Western blot technique. The
dose range of CEZZ and EEZZ that exhibited EBV-EA pro-
teinsuppressionwas20–160 and40–640μg/mL,respectively.
Interestingly,theCEZZattheabove-mentionedrangecaused
complete protein suppression while the EEZZ caused partial
protein suppression at 80–160μg/mL with complete protein
suppression seen only at 320μg/mL. However, the petroleum
ether extract of RZZ (PEZZ) was found to be toxic to Raji
cells at all concentrations used. Further cytotoxic study on
CEZZ and EEZZ using Raji cells indicated that the former
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(90–100% cells death) while the latter was cytotoxic only
at the highest dose used (640μg/mL) with 60% cells death
recorded.Thenoncytotoxicactivitywasalsoseenintheother
six plants’ rhizomes.
4.11. Antiproliferative Activity. Abd Rashid and Lope Pihie
[50], upon investigation carried out to determine the eﬀects
of extracts and fractions of RZZ on the growth of human
breast carcinoma (MCF-7) cell lines, reported that the PEZZ,
followed by EAZZ and MEZZ, exhibited antiproliferative
activity with EC50 value of 4.25 ± 0.05, 8.38 ± 0.08, and
21.31 ± 0.43, respectively. Further partitioning of the MEZZ
gave AEZZ and CEZZ with EC50 of 85.52 ± 0.70 and 9.52 ±
0.04, respectively, while further extraction of EAZZ yielded
E E Z Zw i t hE C 50 value of 59.40 ± 0.42. Based on these
ﬁndings, a bioassay-guided fractionation was performed on
the PEZZ to yield 6 fractions. All fractions were eﬀective
against MCF-7 with EC50 value of A (11.25 ± 0.21), B
(13.60 ± 0.13), C (3.51 ± 0.07), D (11.78 ± 0.17), E (4.07
± 0.09), and F (10.31 ± 0.12). Fraction C was further
fractionated to yield 6 subfractions with only fractions 4
and 5 demonstrating antiproliferative activity against the
cancer cells. The EC50 value recorded was 2.81 ± 0.24 and
2.49 ± 0.13, respectively. Interestingly, these subfractions
were less toxic to normal cells. Comparison was made
with the standard chemotherapeutic agent for breast cancer,
tamoxifen, which was found to produce EC50 value of 4.39
± 0.21 and 2.56 ± 0.59 against MCF-7 and MDBK cells,
respectively.
4.12. Antitumour Activity. In another study, Huang et. al. [4]
reported on the antitumor activity of diethyl ether extract of
RZZ (DEZZ) in cultured P-388D (1) cells by inducing DNA
fragmentation in the cells. Study using animal model of P-
388D (1)-bearing CDF (1) mice also revealed that the DEZZ
could signiﬁcantly prolong the life of cancer-bearing mice
(ILS% = 127.8) at a dosage of 5 mg/kg body weight.
4.13.AntihyperglycemicActivity. Husenetal.[51]carriedout
the screening of AEZZ, at doses of 50, 100, and 150mg/kg
BW, either subjected to freeze-drying process or not, for
potential blood glucose lowering eﬀect in normoglycaemic
and streptozotocin-induced hyperglycaemic rats. Compari-
son with nontreated and 10mg/kg BW-treated rats revealed
that the AEZZ caused no signiﬁcant reduction in blood
glucose level in both groups of rats indicating that the AEZZ
did not have antihyperglycemic activity.
4.14. Antiamoebic and Antigiardial Activity. The chloro-
form, methanol, and water extracts of 12 medicinal plants,
including Z. zerumbet, commonly used by AIDS patients
in southern Thailand, were screened for potential anti-
amoebic activity [52]. The extracts, at a concentration of
1000μg/mL, were ﬁrst tested against Entamoeba histolytica
strain HTH-56:MUTM and HM1:IMSS growing in vitro and
extracts that caused inhibition were chosen and retested with
concentrations ranging from 31.25 to 1000μg/mL against
E. histolytica strain HM1:IMSS. The CEZZ and chloroform
extract of Murraya paniculata, which exhibited the respective
IC50 value of 196.9 and 116.5μg/mL, were classiﬁed as
being “moderately active.” In comparison, the chloroform
extracts of A. galanga, Barleria lupine, B. pandurata, P.
betle and P. chaba,w h i c hp r o d u c e dI C 50 value ranging
from approximately 46 and 91μg/mL, and methanol extract
of B. pandurata (IC50 of approximately 58μg/mL), were
classiﬁed as “active” because their IC50 values were less than
100μg/mL. For validation of methods, metronidazole was
used as a standard drug and produced an IC50 value of
1.1μg/mL.
Various extracts of 12 medicinal plants commonly used
by AIDS patients in southern Thailand were screened
for potential anti-giardial activity [53]. The chloroform,
methanol, and water extracts of the plants, in the doses
ranged between 31.25–1000μg / m L ,a n dar e f e r e n c ed r u g ,
metronidazole, in the concentrations ranging between
0.625–20μg/mL, were tested for their potential to inhibit the
in vitro growth of Giardia intestinalis trophozoites. Despite
the chloroform extract of A. galanga exerting the highest
anti-giardial activity with IC50 and MIC values of 37.73 and
125μg/mL, the CEZZ together with the chloroform extract
of B. pandurata, Eclipta prostrata, P. betle,a n dP. chaba and
the methanol extract of B. pandurata and E. prostrate were
classiﬁed as being active. The CEZZ produced MIC and
IC50 values of 250 and 69.02μg/mL, respectively, while the
MEZZ and AEZZ showed no activity against G. intestinalis.
Metronidazole was found to exhibit MIC and IC50 value of
2.5 and 0.48μg/mL, respectively.
4.15. Antimicrobial Activity. Jantan et al. [2] reported that
EOZZ exhibited a negative antifungal eﬀect when tested
together with another eight species of Zingiberaceae using
the broth microdilution and the disc gel diﬀusion methods.
The antifungal activity was assessed against ﬁve dermato-
phytes (Trichophyton mentagrophytes, T. rubrum, Microspo-
r u mc a n i s ,M .n a n u m ,a n dE p i d e r m o p h y t o nﬂ o c c o s u m ),
three ﬁlamentous fungi (Aspergillus niger, A. fumigatus and
Mucor sp.) and ﬁve strains of yeast (Saccharomyces cerevisiae,
Cryptococcus neoformans, Candida albicans, Ca. tropicalis,
and Torulopsis glabrata).
Further studies were also carried out on the antibacte-
rial activity of CEZZ, MEZZ, and boiling AEZZ together
with another 11 selected Thai medicinal plants used as
self-medication by HIV/AIDS patients in Thailand against
important pathogenic bacteria commonly associated with
AIDS infection, namely, Staphylococcus aureus, methicillin-
resistant S. aureus (MRSA), Streptococcus mutans,a n d
Salmonella typhi [54] using the paper disc agar diﬀusion
method. The Gram-positive bacteria were proven to be
susceptible to CEZZ and chloroform extract of Alpinia
galanga, Boesenbergia rotunda, Piper betel and Spilanthes
acmella, and the methanol extract of B. rotunda.O fa l l
tested bacteria, CEZZ, at the concentration of 250μg/disc,
exhibited antibacterial activity against MRSA, S. aureus and
Streptococcus mutans with inhibition zone of 9.5, 9.8, and
8.6mm, respectively. In comparison to other plants, A.
galanga was found to exert the highest antibacterial activity
followed by B. rotunda and Z. zerumbet. The MIC and MBC
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in this study. Amikacin (10μg/disc), ampicillin (10μg/disc),
aztreonam (30μg/disc), chloramphenicol (30μg/disc), ery-
thromycin (30μg/disc), gentamicin (10μg/disc), kanamycin
(30μg/disc), oxacillin (1μg/disc), penicillin (10μg/disc),
tetracycline (30μg/disc), and vancomycin (30μg/disc) were
usedasstandardreferenceantibiotics.Onlychloramphenicol
and vancomycin successfully inhibited the growth of MRSA,
S. aureus and S. mutans with inhibition zone of 24.5, 23.5,
and 22.3mm and 16.7, 16.6, and 21.5mm, respectively.
In other antibacterial studies using CEZZ, MEZZ, and
boiling AEZZ together with 10 selected Thai medicinal
plants commonly used to treat infections against important
foodborne pathogenic bacteria (e.g., Bacillus cereus, S. aureus,
MRSA, Escherichia coli O157:H7, S. Typhi, and Shigella
sp.), only the CEZZ and the chloroform extract of A.
galanga, B. rotunda, P. betel, and Barleria lupulina exhibited
antibacterial activity [55]. CEZZ, which has no eﬀect against
Gram-negative bacteria, was reported to be active against S.
aureus in the paper disc agar diﬀusion assay. CEZZ was also
tested against 17 clinical isolates of S. aureus.T h eM I Ca n d
MBC values of CEZZ against most clinical S. aureus isolates
were 0.79 and >12.5mg/mL, respectively. CEZZ exerted
promising antistaphylococcal activity against clinical isolates
PSU037, PSU039, PSU040 and PSU051 with minimum
inhibitory concentration (MIC) value of 0.79, 0.79, 0.79,
and 0.39mg/mL, and minimum bactericidal concentration
(MBC) value of 12.50, 3.13, 6.25, and 12.50mg/mL,
respectively. CEZZ was also found to signiﬁcantly inhibit
the growth of MRSA and B. cereus with similar MIC value
of 0.39mg/mL and MBC values of 3.13 and 1.57mg/mL.
Throughout the study, tetracycline and vancomycin were
used as the standard reference drugs. Tetracycline exhibited
antibacterial activity against S. typhi with MIC and MBC
values of approximately 1 and 32mg/mL, respectively. On
the other hand, vancomycin exerted antibacterial activity
against S. aureus ATCC25923 and MRSA PSU039 with
recorded MIC and MBC values of approximately 0.6 and
1.25mg/mL, and 1.25 and 1.25mg/mL, respectively.
4.16. Antimycobacterial Activity. In a study carried out to
determine the antimycobacterial activity of several medicinal
plants, including RZZ, used as self-medication by AIDS
patients in Thailand, 38 crude chloroform, methanol and
waterextractsof12plants weretestedagainstMycobacterium
tuberculosis using the microplate Alamar blue assay [56].
All plants’ extracts tested at the initial concentration of
1000μg/mL inhibited the growth of M. tuberculosis H37Ra.
Activeextractswereretestedatlowerconcentrationstodeter-
mine their MICs. Of all RZZ extracts, only the CEZZ and
MEZZ were found to produce MICs at 125 and 1000μg/mL,
respectively.However,ofallplantstestedonlythechloroform
extract of A. galanga and P. chaba was considered to have
a strong antimycobacterial activity indicated by their MIC
value that was <20μg/mL. As a comparison, rifampin, iso-
niazid, and kanamycin, which were used as standard drugs,
exerted MICs of 0.0023, 0.1, and 2.5μg/mL, respectively.
4.17. Larvicidal Activity. In the ﬁrst attempt to determine
mosquitoes larvicidal activity of RZZ, Tewtrakul et al. [57]
investigate the potential of EEZZ and AEZZ, and VOZZ
against Anopheline larvae (5–75μg/mL) and pupae (25–
200μg/mL). Among the three fractions, the EEZZ exerted
the most eﬀective larvicidal and pupacidal activities (LD50
of 18.9 and 97.4μg/mL, resp.) while the VOZZ exhibited
moderate activities (LD50 of 44.1 and 137.7μg/mL, resp.).
Furthermore,attheconcentrationof75μg/mL,thelarvicidal
eﬀect of EEZZ was approximately 90% compared to the
VOZZ, which displayed only 73.3% larvicidal eﬀect. In
contrast, at the concentration of 200μg/mL, both the EEZZ
and VOZZ exhibited approximately 70% pupacidal activity
while at 25μg/mL, the EEZZ exhibited 23.3% pupacidal
activity as compared to the VOZZ (3.3%). On the other
hand, the AEZZ did not show any larvicidal and pupacidal
activities (LD50 > 2000μg/mL). The control of this study
was 20μL dimethyl sulfoxide (DMSO) and 30μL ethanol in
50mL dH2O. However, no attempt was made to compare the
eﬀectivenessofRZZextractandvolatileoilwithanystandard
drug.
Recent attempt was made to investigate the chemical
compositions and larvicidal potential of essential oils of ﬁve
edible plants, including Z. zerumbet, available in Thailand
against mosquito (Aedes aegypti)v e c t o r s[ 58]. The analysis
of essential oils was carried out using gas chromatography
c o u p l e dw i t hm a s ss p e c t r o m e t r y( G C / M S )a n dr e s u l t e d
in the isolation of 20 compounds from EOZZ with α-
humulene (approximately 31.9%) and zerumbone (approx-
imately 31.7%) being the major components followed by
minor quantities of o-menth-8-ene (8.46%), santolina triene
(5.38%), β-caryophyllene (3.36%), and camphor (3.05%).
Citrus hystrix major components include d-limonene, β-
pinene and terpinen-4-ol; C. reticulata major components
include d-limonene and γ-terpinene; Kaempferia galanga
major components include ethyl-p-methoxycinnamate, pen-
tadecane, and 2-propeonic acid; Syzygium aromaticum
majorcomponentsincludeeugenolandtrans-caryophyllene.
Assessment of larvicidal eﬃcacy of the essential oils demon-
strated that the EOZZ, as well as others, was dose-
dependently toxic with diﬀerent degrees among plant species
against both pyrethroid-susceptible and resistant Ae. aegypti
laboratory strains at LC50,L C 95,a n dL C 99 levels. The
EOZZ, at the concentrations ranging approximately between
39.2–60.9ppm, caused percentage of mortality against 4th
instar larvae of pyrethroid-susceptible Ae. aegypti ranging
approximately between 6.3–94.3%. In addition, the recorded
LC50,L C 95,a n dL C 99 levels for EOZZ were approximately
48.9, 62.2, and 71ppm. In addition, the LC50 value of
EOZZ against pyrethroid-resistant strain was 53.1ppm. As
a comparison, C. reticulate and C. hystrix were considered
to have the most eﬀective larvicidal activity as indicated
by their lowest recorded LC50,L C 95,a n dL C 99 values (15.4,
36.4, and 58.8ppm versus 30.1, 51.0, 68.7ppm, resp.).
Furthermore, the susceptibility of the two strains of Ae.
aegypti to essential oils was slightly diﬀerent but statistically
signiﬁcant. Despite comparing the essential oils activity with
control group, which received only DMSO-distilled water,
the authors did not provide comparison with any reference
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5. Discussion and Conclusion
Z. zerumbet is believed to be native to India and the Malay
Peninsula, which corroborate with its rhizomes particular
uses as food ﬂavoring and appetizer in Malay and Indian
cuisines. Other than that, the RZZ has also been famously
used as medicinal herbs in the Asian, Indian, Chinese,
and Arabic traditional medicines since ancient times. The
claimedmedicinalusesofRZZthroughouttheworldinclude
for the treatment of inﬂammatory- and pain-associated
ailments (i.e., edema, sprain, rheumatism), digestive system-
related ailments (i.e., constipation, diarrhea), and skin
diseases. Most of these claims have been conﬁrmed via in
vitro and in vivo techniques of biological evaluation.
Traditionally, RZZ was used in various ways. For exam-
ple, the Malays used either the fresh or boil rhizomes; the
Chinese macerated the rhizomes in alcohol; the Indians
mixed the rhizome powder with ripe Morinda citrifolia,
cooked and softened the rhizome or mixed the ground
and strained rhizome with water. Based on our literature
searches, seven types of extracts, namely, EOZZ/VOZZ,
EAZZ, MEZZ, EEZZ, AEZZ, PEZZ, and DEZZ, have been
tested for various pharmacological activities using in vivo
and in vitro assays as described above. The AEZZ, EEZZ, and
MEZZ indirectly represent the usual way of using the crude
extract. For example, the AEZZ exhibited anti-inﬂammatory
and antipyretic activities which could be associated to the
Indian traditional medicine uses of mixing the sprained
extract to treat stomach ache. On the other hand, the EEOZ
has been shown to exert antipyretic and larvicidal activities
while MEZZ exhibited antinociceptive, anti-inﬂammatory
activities, which was in line with the Chinese and Taiwanese
traditional uses of the rhizome macerated in alcohol and
as an anti-inﬂammatory adjuvant for stomach ache, sprain,
and fever. It is worth mentioning that some of the claimed
activities in the traditional medicines cured by RZZ and
those activities demonstrated by RZZ extracts could be
associated with inhibition of PGE synthesis, release or action
[6, 7].
The lack of scientiﬁc and clinical data in support of
better understanding of the eﬃcacy and safety of the herbal
drugs has become the major encumbrance to the use of
traditional herbal preparations [59]. This is due largely
to the negligence of the evaluation of the toxicity and
adverse drug reactions of herbal medicines, as they are
considered natural and, thus, erroneously, safe. It is therefore
pertinenttoestablishthesafetyofthesepreparationsthrough
toxicological assessments. In an attempt to study the acute
toxicity eﬀect of RZZ, the AEZZ has been reported to be
safeat 2000mg/kg when given orally to broiler chickens [59].
The selection of dosage regime for the in vivo studies, which
range between 25 and 300mg/kg, was considered acceptable
[60] as they did not exceed the maximum tolerated dose
(MTD) suggested for in vivo studies. The MTD should
not be more than 1000mg/kg/day [61]. Thus, the AEZZ,
EOZZ/VOZZ,MEZZ,andDEZZcanbeconﬁrmedtopossess
in vivo antinociceptive, anti-inﬂammatory, antipyretic, and
antitumour activities. It was, however, diﬃcult to link the
dosage regime used in all assays to the actual crude drug
amount used in traditional medicine as diﬀerent cultures
tend to prepare their medication using diﬀerent methods of
extraction. For example, the Malays used the fresh rhizomes
as a cure for stomach ache while the Chinese macerated
the rhizomes in alcohol and used it as anti-inﬂammatory
adjuvant to treat stomach ache. On the other hand, the claim
of in vitro pharmacological activities by various authors
need to be analyzed carefully before any conclusion could
be made based on the dosage regime used for each of the
study. It is generally accepted that any compounds/extracts
assayed using in vitro techniques should exhibit their activity
at EC50 or IC50 value of less than or equal to 30μg/mL
(≤30μg/mL) in order to be considered active [62]. Based on
the literatures gathered, the selection of dosage regime for
in vitro studies ranges from 10 to 1000μg/mL and taking
into account that the EC50 or IC50 must be ≤30μg/mL, it is
plausible to conﬁrm that EAZZ (EC50 = 8.4μg/mL), MEZZ
(EC50 = 21.3μg/mL), MEZZ-partitioned CEZZ (EC50 =
9.5μg/mL) and PEZZ (EC50 = 4.3μg/mL) possessed antipro-
liferative activity; MEZZ possessed antiplatelet aggregation
a g a i n s tr a b b i tp l a t e l e t( I C 50 = 1.2μg/mL); EEZZ possessed
larvicidal activity (LD50 = 18.9μg/mL). In contrast, several
in vitro pharmacological activities were observed at EC50
or IC50 value that are considered too high and unrealistic
(≥30μg/mL). These include antiplatelet aggregation activity
of MEZZ against human platelet (IC50 = 100.0μg/mL) and
antimycobacterial (MIC = 1000.0μg/mL) activities; antipro-
liferative activity of MEZZ-partitioned AEZZ (EC50 =
85.5μg/mL); antiallergic (IC50 = 91.0μg/mL), antitumour
promoter (at dose range of 40–640μg/mL), antiproliferative
(EC50 = 59.4μg/mL), and pupacidal (LD50 = 97.4μg/mL,
resp.) activities of EEZZ; antiallergic (IC50 = 68.2μg/mL)
and antiproliferative (EC50 = 85.5μg/mL) activities of
AEZZ. Other than unrealistic doses producing pharmaco-
logical activities as described earlier, some of the activities
studied were not properly compared with reference drug.
In most of the treatment, route of administration of
drugs plays an important role and may aﬀect the achieve-
ment of the desired pharmacological action of the drugs.
Herbal medicines are normally taken via an oral route of
administration. However, in some of the preclinical studies
to investigate the pharmacological activity of certain medici-
nal plants, other systemic routes of administration were used
(e.g., intraperitoneal, subcutaneous). Based on our literature
searches, the antinociceptive and anti-inﬂammatory activ-
ities of RZZ were determined using extracts administered
via intraperitoneal or subcutaneous routes. Several reasons
for choosing those systemic routes of administration could
be suggested. Firstly, the authors tried to compare the
eﬀectiveness of antinociceptive activity of extracts with
morphine (reference drug), which is clinically given via
systemic administration. It is not reasonable to compare the
eﬀect of extract with that of reference drug when the extract
was given orally (because it was consumed orally) while the
reference drug (morphine) was given intraperitoneally. Sec-
ondly, since most of the studies were preliminary and aimed
at proving the traditional claims of the particular medicinal
plant, it is believed that the authors did not establish the
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It is known that orally administered compounds/extracts
will undergo ﬁrst-pass hepatic metabolism, and to avoid
this from aﬀecting the extract activity, systemic routes of
administration were chosen.
In most of the studies, in vitro assays were applied to
study the extracts pharmacological activities (e.g., antipro-
liferative, antiplatelet aggregation, and cytotoxicity) because
cell lines permit relatively eﬃcient and economical screening
for chemotherapeutic activity when compared to in vivo
assay systems [63]. Although the data obtained using the in
vitro assays is limited and could not be used as a reliable
source to predict what will be obtained in the in vivo assays,
the former still have the advantage of providing the high-
throughput preliminary data in a less time-consuming man-
ner[64].Otherthanthat,theinvitrostudiescouldbeusedto
provide information for narrowing the scope of subsequent
investigations which required more comprehensive methods
and were time consuming and more expensive [65].
Of all bioactive compound(s) isolated and identiﬁed
from various types of extracts of RZZ, only zerumbone has
been studied extensively. Zerumbone has been demonstrated
to possess in vivo antinociceptive [66], anti-inﬂammatory
[67]a n da n t i t u m o u r[ 4, 68] activities. While in the in
vitro studies, zerumbone has been reported to exhibit
antiproliferative [69] and antiplatelet aggregation [49]a c t i v -
ities. Zederone, isolated from the EEZZ, was suggested to
contribute to the larvicidal activity of the extract [42].
In the present paper, we have reviewed the relevant
literaturetocongregatethebotanical,ethnobotanical,phyto-
chemical, and pharmacological information on Z. zerumbet.
Based on the literature survey, Z. zerumbet demonstrated
various pharmacological activities. However, detail and
careful analysis of the reported data leads us to con-
clude that the plant only possessed promising antinoci-
ceptive, anti-inﬂammatory, antitumour, antiproliferative,
antiplatelet aggregation and larvicidal activities. Despite the
large number of diseases for which RZZ ﬁnds use as a
medicine, our critical analysis of the literature revealed that
itstherapeuticeﬃcacyhasbeenassessedonlyinafewstudies.
In view of the wide range of medicinal uses of RZZ in
Malay, Chinese, Indian, and Arabic folklores as described
in ethnobotanical surveys, it is necessary to conduct more
clinical and pharmacological studies at molecular level to
investigate untapped potential of this plant. For these rea-
sons, extensive pharmacological and chemical experiments,
together with human metabolism, will be a focus for future
studies. Recent increase in interest on herbal medicines
accompanied by increased laboratory investigation into the
pharmacological properties of the bioactive ingredients and
their ability to treat various diseases has contributed to
numerous drugs/herbal extracts entering the international
market. As the recent information shows, it is also possible
that zerumbone might be useful in the development of new
drugs to treat pain- and inﬂammation-associated ailments
and cancer. However, clinicians should remain alert until
more deﬁnitive studies demonstrate the safety, eﬃcacy and
quality of the compound. Last but not the least, this paper
emphasizes the potential of Z. zerumbet to be employed in
the development of new therapeutic drugs and provide the
basis for future research on the application of transitional
medicinal plants.
Abbreviations
RZZ: Rhizome of Z. zerumbet
EOZZ: Essential oil of RZZ
MEZZ: Methanol extract of Z. zerumbet
ALT: Alanine transaminase
ALP: Alkaline phosphatase
AST: Aspartate transaminase
EEZZ: Ethanol extract of RZZ
AEZZ: Aqueous extract of RZZ
VOZZ: Volatile oil of RZZ
PEZZ: Petroleum ether extract of RZZ
DEZZ: Diethyl ether extract of RZZ
MRSA: Methicillin-resistant S. aureus (MRSA)
MIC: Minimum inhibitory concentration
MBC: Minimum bactericidal concentration
DMSO: Dimethyl sulfoxide
MTD: Maximum tolerated dose.
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